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Abstract
Pancreatic cancer has one of the poorest prognoses among all cancers partly because of its persistent resistance
to chemotherapy. The currently limited treatment options for pancreatic cancer underscore the need for more
efficient agents. Because activating Kras mutations initiate and maintain pancreatic cancer, inhibition of this path-
way should have a major therapeutic impact. We synthesized phospho-farnesylthiosalicylic acid (PFTS; MDC-1016)
and evaluated its efficacy, safety, and metabolism in preclinical models of pancreatic cancer. PFTS inhibited the
growth of human pancreatic cancer cells in culture in a concentration- and time-dependent manner. In an MIA
PaCa-2 xenograft mouse model, PFTS at a dose of 50 and 100 mg/kg significantly reduced tumor growth by
62% and 65% (P < .05 vs vehicle control). Furthermore, PFTS prevented pancreatitis-accelerated acinar-to-ductal
metaplasia in mice with activated Kras. PFTS appeared to be safe, with the animals showing no signs of toxicity
during treatment. Following oral administration, PFTS was rapidly absorbed, metabolized to FTS and FTS glucu-
ronide, and distributed through the blood to body organs. Mechanistically, PFTS inhibited Ras-GTP, the active form
of Ras, both in vitro and in vivo, leading to the inhibition of downstream effector pathways c-RAF/mitogen-activated
protein–extracellular signal–regulated kinase (ERK) kinase (MEK)/ERK1/2 kinase and phosphatidylinositol 3-kinase/
AKT. In addition, PFTS proved to be a strong combination partner with phospho-valproic acid, a novel signal trans-
ducer and activator of transcription 3 (STAT3) inhibitor, displaying synergy in the inhibition of pancreatic cancer
growth. In conclusion, PFTS, a direct Ras inhibitor, is an efficacious agent for the treatment of pancreatic cancer in
preclinical models, deserving further evaluation.
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Introduction
Pancreatic cancer, one of the most lethal malignancies in the United
States, is extremely difficult to treat [1], and its prognosis remains
dismal [2]. Therapeutic approaches against the advanced disease have
largely failed and approximately >90% of patients diagnosed with
this malignancy still die within 2 to 8 months. Surgery is rarely
curative because the disease is diagnosed too late for tumor excision
to be beneficial. Gemcitabine, a standard drug for pancreatic cancer
therapy, is minimally effective, improving patient’s survival by only
months [3]. Therefore, it is critical to develop new agents for the
effective management of pancreatic cancer.
Gain-of-function mutations of the Kras oncogene, found in about
one third of human cancers, occur in >90% of pancreatic cancers [4].
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These mutations inhibit GTP hydrolysis at the Ras-binding site,
which results in excessive activity of Ras-GTP, its active form [5].
Ras-GTP stimulates four main downstream effectors, namely, Raf
protein kinase, phosphatidylinositol 3-kinase (PI3K), Ral protein,
and phospholipase C epsilon (PLCɛ). Ras regulates multiple intra-
cellular signaling pathways, with the RAF/mitogen-activated pro-
tein–extracellular signal–regulated kinase (ERK) kinase (MEK)/ERK
kinase pathway being the best understood [6,7]. In response to growth
factor stimulation or oncogene activation, the RAF/MEK/ERK path-
way can modulate the expression/activity of D- and E-type cyclins
and cyclin-dependent kinases to regulate G1-to-S cell cycle phase pro-
gression [8]. Not surprisingly, the RAF/MEK/ERK pathway is a major
target for therapeutic intervention [9,10]. AKT, also downstream of
Ras activation, regulates cell proliferation, survival/apoptosis, angio-
genesis, metabolism, and protein synthesis [11,12]. AKT activation
by phosphorylation, frequent in pancreatic cancer, is associated with
poor prognosis [13]. Inhibition of the PI3K/AKT pathway sensitizes
pancreatic cancer cells to the apoptotic effect of chemotherapy [14].
Oncogenic Kras is essential for both the initiation and mainte-
nance of pancreatic cancer [15]. During all stages of pancreatic carcino-
genesis, Kras upregulates inflammatory and signaling pathways that
mediate paracrine interactions between epithelia and their surrounding
microenvironment, and these Kras-dependent pathways drive tumori-
genesis [16]. Given the predominant role of Ras oncogene in pancreatic
carcinogenesis, there is an intense ongoing effort to identify inhibitors
of the Ras protein [15]. S -trans,trans-farnesylthiosalicylic acid (FTS,
Salirasib) is a Ras inhibitor [17], which interferes with Ras membrane
interactions crucial for Ras-dependent transformation [18]. Goldberg
et al. have shown that modifications of the FTS carboxylic group by
esterification or amidation yield compounds with improved growth
inhibitory activity compared to FTS [19]. We have also demonstrated
that covalent modifications of several carboxylic nonsteroidal anti-
inflammatory drugs generate compounds of superior efficacy and
safety [20–22]. With this in mind, we synthesized the novel phospho-
FTS (PFTS; MDC-1016), following the formula FTS–butane-diethyl
phosphate (Figure 1A).
In the present study, we examined, for the first time, the efficacy,
safety, and metabolism of PFTS in pancreatic cancer and its mech-
anism of action. Our data show that PFTS inhibits the growth of
human pancreatic cancer in nude mice and prevents acinar-to-ductal
metaplasia in mice with activated Kras. Furthermore, PFTS sup-
presses Ras activation, leading to strong inhibition of the RAF/MEK/
ERK and PI3K/AKTpathways, and sensitizes the pancreatic cancer cells
to the cytotoxic effects of phospho-valproic acid (P-V), a novel signal
transducer and activator of transcription 3 (STAT3) inhibitor [23].
Materials and Methods
Reagents
PFTS (MDC-1016) and P-V (MDC-1112) were gifts fromMedicon
Pharmaceuticals, Inc (Stony Brook, NY). FTS was purchased from
Figure 1. PFTS inhibits pancreatic cancer growth in vitro. (A) Chemical structure of PFTS (MDC-1016). (B) PFTS inhibits pancreatic cancer cell
growth in a concentration-dependent manner. Cell growth was determined in AsPC-1, CFPAC-1, Capan-2, Panc-1, and MIA PaCa-2 after
treatment with escalating concentrations of PFTS for 24 hours. Results are expressed as percentage of control. (C) PFTS inhibits MIA
PaCa-2 cell growth more potently than FTS. Cell growth was determined in MIA PaCa-2 after treatment with escalating concentrations
of PFTS or FTS for 72 hours. Results are expressed as percentage of control. (D) PFTS inhibits pancreatic cancer cell colony formation in
a concentration-dependent manner. FTS (20 μM) led to a 42% and 38% inhibition in colony formation in MIA PaCa-2 and BxPC-3 cells.
Neoplasia Vol. 15, No. 10, 2013 Phospho-FTS Inhibits Pancreatic Cancer Growth Mackenzie et al. 1185
Cayman Chemical (Ann Arbor, MI). For PFTS, FTS, and P-V,
we prepared a 100 mM stock solution in DMSO. In all cell culture
media, the final DMSO concentration was adjusted to 1%. Annexin
V was purchased from Invitrogen (Grand Island, NY). All general
solvents and reagents were of HPLC grade or the highest grade
commercially available.
Cell Culture
Human pancreatic cancer (BxPC-3, AsPC-1, CFPAC-1, Capan-2,
Panc-1, and MIA PaCa-2) cell lines were grown as monolayers in the
specific medium suggested by the American Type Culture Collection
(Manassas, VA) and supplementedwith 10% fetal calf serum (Mediatech,
Herndon, VA), penicillin (50 U/ml), and streptomycin (50 μg/ml; Life
Technologies, Grand Island, NY). Cells were incubated at 37°C in 5%
CO2. Cells were seeded at 5.5 × 10
4 cells/cm2 and allowed to attach
overnight, and the following morning, the cells were treated with the
test agents as indicated.
Cell Viability Assay
Following the treatment with various concentrations of PFTS or
FTS for 24, 48, or 72 hours, the reduction of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide dye was determined accord-
ing to the manufacturer’s protocol (Promega, Madison, WI).
Colony Assay
MIA PaCa-2 and BxPC-3 cells, plated onto six-well plates (3000 cells
per well), were treated with PFTS or FTS for 10 days, with their media
replaced every 3 days. The cells were then stained with 1% crystal violet
in borate-buffered saline (0.1 M, pH 9.3) and 0.02% ethanol. Follow-
ing lysis with 1% sodium dodecyl sulfate (SDS), the absorbance was
read at 570 nm.
Apoptosis
To measure apoptosis and necrosis, cells (1.0 × 105 cells per well)
were treated with various concentrations of PFTS or P-V or both for
24 hours. Briefly, after the treatment with the test compounds, cells
were trypsinized and stained with annexin V–fluorescein isothio-
cyanate (×100 dilution; Invitrogen) and propidium iodide (0.5 μg/ml;
Sigma, St Louis,MO), and the fluorescence intensities were analyzed by
FACSCalibur (BD Biosciences, San Jose, CA).
Western Blot Analysis
Total cell fractions were obtained as previously described [24].
Aliquots of total fractions containing 25 to 40 μg of protein were
separated by reducing 10% to 12.5% (wt/vol) polyacrylamide gel
electrophoresis (PAGE) and electroblotted to nitrocellulose mem-
branes. The membranes were probed overnight with Ras (Thermo
Scientific, Rockford, IL), c-RAF (Cat. No. 9422), p-c-RAF Ser259
(Cat. No. 9422), p-ERK1/2 Thr202/Tyr204 (Cat. No. 4376),
ERK1/2 (Cat. No. 4370), p-MEK1/2 Ser217/221 (Cat. No. 9154),
MEK1/2 (Cat. No. 9122), p-AKT Ser473 (Cat. No. 4060), and
AKT (Cat. No. 4691; Cell Signaling Technology, Danvers, MA)
antibodies (1:1000 dilution). β-Actin (Sigma) was used as the loading
control. After incubation, for 90 minutes at room temperature, in the
presence of the secondary antibody (HRP conjugated; 1:5000 dilu-
tion), the conjugates were visualized by chemiluminescence.
Ras Pull-Down Assays and Immunoblot Analysis
Freshly isolated tumors were weighed and then homogenized
(10% wt/vol) in lysis buffer [25]. Total amounts of Ras were deter-
mined in samples (60 μg of protein) of each lysate by SDS-PAGE
followed by immunoblot analysis with pan-Ras antibody (Thermo
Scientific). The amounts of Ras-GTP in 800 μg of protein of total tumor
lysates were determined by the glutathione S -transferase–Ras-binding
domain of Raf pull-down assay, as described elsewhere [25]. The pull-
down Ras-GTP was subjected to SDS-PAGE followed by immunoblot
analysis with pan-Ras Ab. Protein bands were visualized by enhanced
chemiluminescence and quantified by densitometry using ImageJ
computer software (National Institutes of Health, Bethesda, MD).
Animal Studies
All animal studies were approved by the Institutional Animal Care
and Use Committee at Stony Brook University (Stony Brook, NY).
Toxicity of PFTS in mice. We evaluated in mice the potential
acute toxicity of PFTS. Groups of 6-week-old female BALB/c mice
(five mice per group) were given 0, 75, 150, 250, and 350 mg/kg
PFTS by oral gavage once a day for 3 weeks. Body weights were
recorded twice weekly. Animals were killed at 3 weeks, and their
organs were examined for any signs of toxicity.
Pharmacokinetic studies in mice. PFTS (200 mg/kg) or an equi-
molar dose of FTS (126 mg/kg) was administered as a single treat-
ment by gastric gavage to female BALB/c mice. Mice were killed at
various time points after drug administration, and blood and organs
were collected. Blood was immediately centrifuged, and the resulting
plasma was deproteinized by immediately mixing it with a two-fold
volume of CH3CN. PFTS, FTS, and its metabolites were analyzed
by HPLC as described below.
Efficacy study in nude mouse xenografts. Female immune-deficient
BALB/c nude mice at 6 weeks of age were purchased from Charles
River Laboratories (Wilmington, MA) and were maintained in
pathogen-free conditions with irradiated chow. Animals were bilat-
erally, subcutaneously (s.c.) injected with 1.5 × 106 MIA PaCa-2
cells per tumor in 0.1 ml of sterile phosphate-buffered saline. When
MIA PaCa-2 cells reached palpable tumors, mice (n = 7 per group)
were divided randomly into three groups receiving control, 50 mg/kg
PFTS, or 100 mg/kg PFTS in corn oil, which were given orally to
mice five times per week during 25 days. Only corn oil was given to
the untreated control mice. Body weight was measured once a week,
whereas tumors were measured twice weekly. Tumor sizes were
calculated by the following formula: [length × width × (length +
width/2) × 0.56] in millimeters. At the end of the experiments,
animals were killed by CO2 asphyxiation and tumor weights were
measured after their careful resection. Tumor tissue was collected
for analysis.
p48-Cre;LSL-KrasG12D mouse studies. p48-Cre;LSL-KrasG12D
mice (2-3 months old) in C57Bl/6J background were injected intra-
peritoneally with cerulein (50 μg/kg hourly, four times per day, 2 days
per week; 3 days of injection). Cerulein-injected mice were divided
into vehicle (n = 3) and PFTS (n = 3) groups. PFTS (100 mg/kg)
was given 5 days per week by oral gavage, starting the treatment on
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the day of the first cerulein injection. On day 9, mice were killed and
the pancreas was excised, fixed in formalin, and processed for mor-
phologic and immunohistochemical studies.
Immunohistochemistry
Immunohistochemical staining for Ki-67, α-amylase, p-c-RAF,
and p-ERK1/2 was performed as previously described [26].
Determination of Apoptosis
Apoptosis was determined immunohistochemically by the terminal
deoxynucleotidyl transferase–mediated deoxyuridine triphosphate–
biotin nick end labeling (TUNEL) assay [22]. Formalin-fixed tissues
were determined using the In Situ Cell Death Detection Kit, POD
(Roche, Indianapolis, IN) as per the manufacturer’s instructions.
Treatment of samples with DNAse I was used as positive control.
Scoring for TUNEL and immunohistochemistry. At least 10 fields
per sample were scored by an investigator blinded to the identity of the
samples. We calculated the percentage of proliferating and apoptotic
cells by dividing the number of labeled cells by the number of cells
in each field and multiplying by 100.
HPLC-UV Analysis
The HPLC system consisted of a Waters Alliance 2695 Separation
Module equipped with a Waters 2998 Photodiode Array Detector
(262 nm) and a Thermo Hypersil BDS C18 column (150 × 4.6 mm,
particle size of 3 μm). The mobile phase consisted of a gradient be-
tween an aqueous phase [trifluoroacetic acid/CH3CN/H2O, 0.1:4.9:95
(vol/vol/vol)] andCH3CNat a flow rate of 1ml/min at 30°C.A gradient
elution from 50% to 100% CH3CN from 0 to 6 minutes was applied
and maintained at 100% CH3CN until 8 minutes.
Liquid Chromatography-Tandem Mass Spectrometry Analysis
The LC-MS/MS system consisted of Thermo TSQ Quantum
Access (Thermo Fisher Scientific, Waltham, MA) triple quadrupole
mass spectrometer interfaced by an electrospray ionization probe with
an UltiMate 3000 HPLC system (Dionex Corporation, Sunnyvale,
CA). Chromatographic separations were achieved on a Luna C18
column (150 × 2 mm), and the mobile phase consisted of a gradient
from 10% to 95% CH3CN.
Statistical Analysis
The data, obtained from at least three independent experiments,
were expressed as means ± SEM. Statistical evaluation was performed
by one-factor analysis of variance followed by Tukey test for multiple
comparisons. P < .05 was regarded statistically significant.
Results
PFTS Inhibits the Growth of Human Pancreatic Cancer Cells
in Culture
Our first goal was to establish the efficacy of PFTS in pancreatic
cancer cells in culture. We treated a panel of five human pancreatic
cancer cell lines with or without escalating concentrations of PFTS
(5-320 μM) for 24 hours. As shown in Figure 1B, PFTS reduces
pancreatic cancer cell growth in a concentration-dependent manner
in all the cell lines tested. For instance, at 24 hours, PFTS (5 μM)
reduced cell growth in AsPC-1 and Panc-1 cells by 43% and 34%
(P < .05), respectively.
We then compared the potency of PFTS to that of FTS, its parent
compound, in MIA PaCa-2–treated cells for 72 hours. PFTS inhib-
ited the growth of MIA PaCa-2 pancreatic cancer cells more potently
than FTS (Figure 1C ); their respective 72-hour half maximal inhib-
itory concentration (IC50) values were 44.1 ± 2.8 μM (mean ± SEM
for this and all subsequent values) and >80 μM, representing a >1.8-
fold enhancement.
We also examined the effect of PFTS and FTS on colony forma-
tion in two pancreatic cancer cell lines. PFTS inhibited colony for-
mation in a concentration-dependent manner and was significantly
superior to FTS (Figure 1D). For example, PFTS (20 μM) reduced
colony formation by 71% and 68%, whereas FTS, at the same con-
centration, reduced it by 42% and 38% in MIA PaCa-2 and BxPC-3
cells, respectively. The difference in potency between PFTS and FTS
groups was significant (P < .01) in both cell lines.
PFTS Inhibits the Growth of Human Pancreatic Xenografts in
Nude Mice
We next assessed the in vivo chemotherapeutic potential of PFTS
using a pancreatic cancer xenograft model. MIA PaCa-2 cells s.c.
injected into athymic nude mice gave rise to exponentially growing
tumors. Once the tumors reached ∼200 mm3, the mice were treated
orally either with PFTS (50 or 100 mg/kg) or with vehicle. On
day 25 of treatment, the percentage of tumor volume increase over
baseline for the vehicle control, PFTS (50 mg/kg per day), and PFTS
(100 mg/kg per day) groups were 294.2 ± 68.4, 172 ± 60.6, and
167 ± 50.3, respectively. Although PFTS treatment did not lead
to tumor regression, 50 and 100 mg/kg PFTS presented a 62%
and 65% reduction in the rate of tumor growth from baseline
for the two PFTS doses, respectively (P < .05 for both; Figure 2,
A and B).
To investigate the mechanism by which PFTS reduced tumor
growth, we determined cell proliferation (Ki-67 immunohistochem-
istry) and apoptosis (TUNEL assay) in tumor tissue sections from
control and PFTS-treated mice. Both Ki-67 immunohistochemistry
(IHC) and TUNEL staining showed nuclear positive. The percent-
age of positive cells in the tumors for both Ki-67 and TUNEL stain-
ing was counted and calculated as the results. Compared to controls,
PFTS (100 mg/kg) inhibited cell proliferation by 44% (P < .05) and
increased apoptosis by 102% (P < .01; Figure 2C ).
PFTS Prevents against Pancreatitis-Accelerated Pancreatic
Intraepithelial Neoplasia Formation in Mice with
Activated Kras
Because chronic pancreatitis is a significant risk factor for pan-
creatic cancer [27,28], we investigated whether PFTS inhibits Kras-
driven pancreatic carcinogenesis in the setting of pancreatitis induced
by cerulein.
In p48-Cre;KrasG12D mice, cerulein treatment (4 hourly injections,
two times per week) induced acinar-to-ductal metaplasia in all vehicle-
treated animals, significantly replacing the exocrine compartment
(Figure 3). This effect was accompanied by lower expression of amy-
lase, an acinar marker, and enhanced Alcian blue staining, which
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characterizes pancreatic intraepithelial neoplasias (PanINs) [29].
PFTS (100 mg/kg) treatment prevented cerulein-induced acinar-to-
ductal metaplasia, reducing PanIN formation, an effect associated with
four-fold increased amylase expression (P < .05) and 43% decreased
Alcian blue staining areas compared to cerulein-treated controls (P <
.05; Figure 3).
Safety of PFTS in Mice
In the efficacy study mentioned above, PFTS was well tolerated,
with the mice showing no weight loss or other signs of toxicity dur-
ing treatment. For instance, on the day before killing, body weight in
the three groups of mice was given as follows: control = 21.1 ± 1.5 g;
PFTS (50 mg/kg) = 20.7 ± 0.7 g; PFTS (100 mg/kg) = 21.4 ± 1.5 g.
We also examined the toxicity of PFTS in mice. Groups of 6-week-
old female BALB/c mice (five mice per group) were given 0, 75, 150,
250, and 350 mg/kg PFTS by oral gavage once a day for 3 weeks.
Body weights were recorded twice weekly. All of the PFTS-treated
animals showed no signs of toxicity and were alive and healthy
throughout the study. The body weights of vehicle- and PFTS-treated
animals were comparable throughout the study.
Finally, we determined that the (subchronic)maximum tolerated dose
of PFTS (3-week period of observation) is at least 350 mg/kg per day.
Pharmacokinetic Study of PFTS
To study the pharmacokinetic properties of PFTS, we adminis-
tered to mice by oral gavage a single dose of PFTS (200 mg/kg) or
an equimolar dose of FTS (126 mg/kg). Two major metabolites, FTS
and FTS glucuronide, were readily detected in the plasma. FTS glu-
curonide was identified by LC-MS/MS analysis. The mass spectrum
of FTS glucuronide showed an [M-H]− ion at m/z 533, which was
further fragmented at its glucuronide bond to generate m/z 357
(Figure 4A).
Following PFTS administration, the plasma levels of the two
metabolites increased rapidly and their concentration peaked 1 hour
Figure 2. PFTS inhibits the growth of pancreatic cancer xenografts. (A) Inhibition of MIA PaCa-2 tumor growth in nude mouse by PFTS.
MIA PaCa-2 cells were injected s.c. into the flank areas of nude mice, and when palpable tumors were observed, the mice received PFTS
(50 or 100 mg/kg per day) in corn oil or just corn oil (control) by oral gavage for 25 days. (B) Representative image of mice bearing
tumors. (C) Representative images (×20) of tissue sections from xenograft tumors treated with either vehicle (control) or PFTS and
stained for Ki-67 expression (proliferation marker) or by the TUNEL method (apoptosis). The proliferation and apoptosis indices of
xenograft tumors were determined and expressed as means ± SEM (*P < .05 for both).
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later. Specifically for FTS, Tmax = 1 hour and Cmax = 29.7 μM, and for
FTS glucuronide, Tmax = 1 hour and Cmax = 10.3 μM (Figure 4B),
indicating that PFTS was rapidly absorbed, metabolized, and dis-
tributed to the blood. The level of intact PFTS in murine plasma
was ∼1 μM.
With FTS, we obtained similar results: for FTS, Tmax = 1 hour and
Cmax = 19.8 μM, and for FTS glucuronide, Tmax = 2 hours and Cmax =
37.4 μM (Figure 4B). When we calculated the AUC0–24 hours for these
compounds, it became clear that both generated similar cumulative
levels of FTS [area under the curve (AUC)0–24 hours for PFTS was
114 μMxh and 116 μMxh for FTS]. In contrast, the glucuronidation
of PFTS is less extensive than that of FTS. For example, the
corresponding AUC0–24 hours values for FTS glucuronide were 50.9
and 187.8 μMxh, indicating that PFTS generated 3.7-fold less of this
metabolite compared to an equimolar amount of FTS (Figure 4B).
To evaluate the biodistribution of PFTS in mice, we measured the
levels of PFTS and its metabolites in the heart, kidney, liver, pan-
creas, and intestine. One hour following its administration by oral
gavage, PFTS was detected in large amounts in the intestine and,
to a lesser extent, in the pancreas. In the liver, kidney, and heart,
only FTS and FTS glucuronide were detectable (Figure 4C ). Thus,
despite its rapid hydrolysis in blood, PFTS can partially survive in
appreciable amounts in the pancreas but is rapidly metabolized by
the liver.
One hour following FTS administration, FTS and FTS glucuronide
were detected in all the organs tested. Interestingly, the levels of FTS
glucuronide were significantly higher in the intestine, kidney, and liver
compared to the heart and pancreas (Figure 4C ), and these were almost
double than those obtained with PFTS. Taken together with the
plasma levels, these findings make it clear that glucuronidation is a
Figure 3. PFTS protects against acute pancreatitis-accelerated PanIN formation. (A) Cerulein treatment protocol. Mice with activated
Kras (p48-Cre;LSL-KrasG12D) were injected with cerulein and killed 9 days post-injection. At the day of the first injection of cerulein, mice
were treated with PFTS (100 mg/kg per day) as shown. (B) The following stains were performed. (Top) hematoxylin and eosin (H&E) stain.
Fewer ductal and more acinar structures were observed in the PFTS-treated mice (×4); scale bars, 200 μm. (Middle) Amylase. PFTS-
treated mice retained larger areas of amylase-expressing epithelium (×10); scale bars, 100 μm. (Bottom) Alcian blue stain (×20); scale
bars, 50 μm. (C) The percentages of amylase-positive area and Alcian blue–positive staining per field were quantified and expressed as
means ± SEM (*P < .05 for both).
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Figure 4. Pharmacokinetic analysis of PFTS. (A) MS spectrum of a major metabolite of PFTS. (Left) MS spectrum of the FTS glucuronide
fraction collected from HPLC. (Right) MS/MS spectrum of the major fragment ions of the FTS glucuronide ion. (B) The pharmacokinetics
of PFTS and FTS administered in corn oil to mice. PFTS (200 mg/kg) or an equimolar dose of FTS (126 mg/kg) was administered to mice
as a single dose orally in corn oil. Plasma levels of PFTS and FTS metabolites were determined at the times shown. (C) Biodistribution of
PFTS and FTS in mouse tissues after 1 hour of its administration. The heart, kidneys, liver, pancreas, and intestines of the mice studied
in B were harvested, and PFTS, FTS, and its metabolites were measured as in Materials and Methods section. Data were expressed as
picomoles of the metabolite per milligram of protein in each tissue.
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significant pathway for both PFTS and FTS, but quantitatively, it is far
more important for the latter.
PFTS Inhibits Ras Activation and Its Downstream Effectors
ERK and AKT
We examined whether the pancreatic cancer growth inhibitory
effect of PFTS was associated with down-regulation of Ras signaling,
as is the case with FTS [19,25]. For this purpose, we used the Ras-
GTP pull-down assay. In Panc-1 cells, PFTS significantly inhibited
active Ras (Ras-GTP) in a concentration-dependent manner, and this
decrease was more pronounced than the one observed with FTS
(Figure 5). The inhibition of Ras by PFTS led to a significant time-
dependent inhibition of the RAF/MEK/ERK and PI3K/AKT path-
ways, two downstream effectors of Ras (Figure 5C ).
The inhibition of Ras by PFTS was confirmed in vivo. We used
the Ras-GTP pull-down assay to test the capacity of PFTS to inhibit
active Ras in fresh protein lysates from MIA PaCa-2 xenografts.
Compared to controls, 50 and 100 mg/kg PFTS reduced RAS acti-
vation in xenografts by 62% and 70%, respectively (P < .01 for both;
Figure 6A). The suppression of Ras was accompanied by inhibition
of p-ERK and p-AKT, as determined by immunoblot analysis
(Figure 6B). Moreover, immunostaining of xenograft tissue sections
revealed that PFTS reduced the expression of p-c-RAF and p-ERK1/
2 by 73% and 71%, respectively, compared to control (P < .01;
Figure 6C ).
Taken together, these in vivo results, in agreement with our in vitro
results, suggest that Ras is a critical molecular target of PFTS, likely
accounting for its pancreatic cancer growth inhibitory effect.
PFTS Synergizes with P-V to Enhance Human Pancreatic
Cancer Growth Inhibition
Growing preclinical and clinical evidence indicates that combi-
nation therapies increase the anticancer efficacy without increasing
toxicity [30]. Besides Ras signaling, STAT3, which is overexpressed
in pancreatic cancer, has been described as a key driver of the pro-
gression into advanced pancreatic cancer [29,31]. Therefore, we eval-
uated in BxPC-3 and MIA PaCa-2 cells the potential synergy between
PFTS and P-V, a novel STAT3 inhibitor, efficacious in pancreatic
cancer [23]. Using isobolograms, we observed that in MIA PaCa-2
cells, there is a clear-cut pharmacological synergy between PFTS
Figure 5. PFTS inhibits Ras activation and reduces ERK1/2 and AKT activation in pancreatic cancer cells. (A) Immunoblots of Ras-GTP
(active Ras) and total Kras in Panc-1 cells treated without or with PFTS, as indicated, for 24 hours. (B) Immunoblots of Ras-GTP (active
Ras) in cell protein extracts from Panc-1 cells treated with 50 μM PFTS or 50 μM FTS for 24 hours. *P < .05 versus control. (C) Immuno-
blots of p-c-RAF, c-RAF, p-MEK, MEK, p-AKT, and AKT in whole-cell protein extracts from Panc-1 cells treated with PFTS as indicated.
Loading control, β-actin.
Neoplasia Vol. 15, No. 10, 2013 Phospho-FTS Inhibits Pancreatic Cancer Growth Mackenzie et al. 1191
and P-V in inhibiting cell growth (Figure 7, A and B). However, in
BxPC-3 cells, the cytotoxic effect of PFTS and P-V was only additive.
In addition, as shown in Figure 7C , there is also a clear-cut synergistic
effect in the induction of apoptosis in MIA PaCa-2 cells but not in
BxPC-3 cells. After 24 hours of treatment, PFTS (1× IC50) plus P-V
(1× IC50) increased annexin V(+) cells by 4.5-fold over control com-
pared to 2.4-fold for P-V alone and 1.9-fold for PFTS (Figure 7C ).
These results suggest that P-V could be a useful combination partner
of PFTS in the treatment of Ras mutant cancers.
Discussion
Inoperable pancreatic cancer remains a devastating malignancy
because of the lack of efficacious treatments. In the present
study, we show that the novel PFTS is effective and safe against
pancreatic cancer in mice by inhibiting Ras activation and its
downstream effectors ERK1/2 and AKT pathways. The anticancer
efficacy of PFTS, accompanied by its apparent lack of toxicity,
makes it a promising drug candidate for the treatment of pan-
creatic cancer.
Gain-of-function mutations in the Kras oncogene constitute
one of the main genetic alterations found in pancreatic cancer. Kras
activity is not only essential for pancreatic tumor formation and
development, but also, at least in mice, the requirement for Kras is
continuous [15,16]. Further stressing the importance of Kras is the
finding that inactivation of oncogenic Ras in mice results in tumor
shrinkage [16]. Thus, Ras is widely considered a therapeutic target of
exceptional importance.
Figure 6. PFTS inhibits Ras activation and reduces ERK1/2 and AKT activation in pancreatic xenografts. (A) Immunoblots of Ras-GTP
(active Ras) and total Kras. Samples of three control tumors and of three tumors of each PFTS-treated mouse were subjected to the
determination of total Kras and Ras-GTP. (Upper panel) Immunoblots. (Lower panel) Levels of Ras-GTP were quantified by densitometry
(AU) and expressed as mean ± SD values. *P< .01 versus control. (B) Immunoblots of p-ERK, ERK, p-AKT, and AKT in whole-cell protein
extracts from MIA PaCa-2 xenografts. Loading control, β-actin. (C) Images of tissue sections from xenograft tumors treated without or
with PFTS and stained for p-ERK expression. The percentage of p-ERK–positive cells per field was determined and expressed as mean ±
SEM (*P < .03).
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The novel PFTS is a strong inhibitor of Ras activation. Both PFTS
and FTS produced a robust inhibition of RAS activation without a
significant decrease in total Ras levels. This is in contrast to findings
by other groups who have demonstrated that the inhibition of
Ras activation is followed by a decrease in the levels of total Ras
[17,19]. At present, there is no readily available explanation for this
seeming discrepancy.
PFTS was generated by modifying the carboxylic group of FTS to
enhance its efficacy, as we have done with other anticancer agents
[20–22,26,32,33]. PFTS has a higher capacity to inhibit Ras activity
and is more effective than FTS in suppressing pancreatic cancer cell
growth. That PFTS is more effective than FTS could be attributed
directly to the butane-diethyl phosphate modification that was added
to be parent moiety. Of note, we have also demonstrated that similar
modifications of several carboxylic nonsteroidal anti-inflammatory
drugs generated compounds of superior efficacy and safety [20–22].
In agreement to our results, Goldberg et al. demonstrated that specific
modifications of the carboxylic group of FTS by esterification or
amidation yield compounds with improved growth inhibitory activity
compared to FTS [19].
We used two complementary preclinical models to evaluate the
anticancer effect of PFTS in pancreatic cancer. These included 1) an
MIA PaCa-2 Kras mutant xenograft model in nude mice and 2) a
Kras-driven pancreatic carcinogenesis mouse model. On the basis of
Figure 7. P-V enhances PFTS-induced inhibition of pancreatic cancer cell growth. (A) Cell viability was determined in MIA PaCa-2 and
BxPC-3 cells after 24 hours of incubation with P-V, PFTS, or both. Results are expressed as percentage of control. (B) In the iso-
bolograms, the additivity line connects the IC50 value of each compound used alone. A and B represent two different dose pairs of
each compound (their respective concentrations are shown in parentheses). The location of both A and B below the additivity line
signifies synergy, whereas the location of the points close to the line signifies additivity. (C) The percentages of apoptotic cells were
determined by flow cytometry using dual staining (annexin V and propidium iodide). The percentage of annexin V(+) cells was calcu-
lated, and results are expressed as percentage of control. Of note, the drug concentrations refer to the 24-hour IC50 for each drug in
each particular cell line, as calculated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
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our findings from human pancreatic cancer xenografts, which allowed
us to evaluate the therapeutic potential of PFTS, the inhibition of
pancreatic cancer growth by PFTS was strong, significantly reducing
the rate of growth of MIA PaCa-2 tumors by up to 65% in nude mice
without causing any toxic side effects. We further examined the chemo-
preventive effect of PFTS on the earliest phases of pancreatic cancer
development using a Kras/pancreatitis-associated carcinogenesis model.
In this model, Krasmutations are important contributors to the altered
pancreatic plasticity and acinar-to-ductal metaplasia [16]. PFTS was
efficacious in reducing acinar-to-ductal metaplasia and in preventing
PanIN formation. Overall, these two preclinical models indicate that
PFTS is efficacious in pancreatic cancer.
Our animal studies assessed multiple parameters of toxicity. PFTS
was well tolerated, showing essentially no signs of toxicity. This find-
ing is in agreement with previous reports showing that selective
blocking of activated Ras proteins inhibits Ras transformation in
animal models, with no accompanying toxicity [25]. The pharmaco-
kinetic and biodistribution studies demonstrated that following its
administration to mice, PFTS is rapidly absorbed, metabolized,
and distributed into blood and other tissues. In addition to intact
PFTS, we have identified two additional metabolites, FTS and
FTS glucuronide, which are present at substantial concentrations.
A striking finding was the substantially (3.7-fold less) limited glucu-
ronidation of PFTS compared to FTS, despite the fact that both
compounds generated essentially identical plasma levels of FTS. It
is conceivable that PFTS may activate additional metabolic pathways
that we have not identified or it suppresses directly the glucuronida-
tion pathway.
By targeting Ras, PFTS inhibited two prominent downstream
pathways, RAF/MEK/ERK and PI3K/AKT. The Ras-activated
RAF/MEK/ERK pathway has been implicated in a wide variety of
processes in the cancer cell including the regulation of cell mortality,
apoptosis, angiogenesis, invasion and metastasis, and cell division
cycle [8]. A consequence of the suppression of Ras activation by
PFTS is the inhibition of ERK phosphorylation both in vitro and
in vivo. Because of the requirement of RAF/MEK/ERK signaling
in the aberrant behavior of the pancreatic cancer cell, its down-
regulation could explain, in part, the reduction in cell proliferation
observed in PFTS-treated tumors.
The activation of AKT is common in pancreatic cancer, and its
inhibition sensitizes cells to the apoptotic effects of chemotherapy
[13,14]. Activation of AKT by upstream signals, such as Ras, confers
a survival advantage that includes resistance to the apoptotic effects of
chemotherapy and radiotherapy. Remarkably, there is a significant
correlation between activation of AKT and poorer survival in patients
with pancreatic cancer [34]. Therefore, our findings provide clinical
relevance to the inhibition of AKT by PFTS and suggest that Ras
inhibition could be beneficial in inhibiting downstream effectors
such as AKT.
Combining agents for the treatment of cancer is a promising area
of investigation [35]. The possible favorable outcomes for drug com-
binations include 1) increasing the efficacy of the therapeutic effect,
2) avoiding toxicity by decreasing drug dosage while increasing or
maintaining the same efficacy, and 3) minimizing the development
of drug resistance. Because of these benefits, drug combinations are
being widely used and are an excellent choice for the treatment of
cancer [35]. On the basis of the critical role that Kras and STAT3
play in pancreatic cancer [16,36], these pathways are attractive tar-
gets for drug development. Interestingly, PFTS is a successful com-
bination partner of the novel STAT3 inhibitor P-V [23], the two of
them synergizing to inhibit the growth of pancreatic cancer cells.
We therefore believe that PFTS is a promising candidate agent for
the treatment of pancreatic cancer and may also serve as a chemo-
sensitizer to improve the therapeutic efficacy of other anticancer drugs.
In conclusion, the novel compound PFTS is an effective anti-
cancer agent in preclinical models of pancreatic cancer, acting primarily
through the inhibition of Kras activation and its downstream effectors.
Taken together, our results point out to the potential of PFTS, a novel
Ras inhibitor, as a new agent against pancreatic cancer and merit
further evaluation.
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